Welcome to our dedicated page for Eiger BioPharmaceuticals news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals stock.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) is a commercial-stage biopharmaceutical company headquartered at 500 Crescent Ct Ste 300, Dallas, Texas. The company focuses on the development of innovative therapies for rare and ultra-rare diseases.
Recently, Eiger has redirected its efforts towards the development of avexitide for hyperinsulinemic hypoglycemia indications. This includes significant potential in treating post-bariatric hypoglycemia (PBH), where Phase 2 clinical trials have shown promising results, and the FDA has provided alignment on Phase 3 endpoints and study design. Eiger also plans to develop avexitide for congenital hyperinsulinism as a secondary indication.
The company continues to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL). Eiger recently received marketing approval for Zokinvy in Japan through a partnership with AnGes, Inc., further expanding its global reach.
In a strategic move, Eiger is exploring partnering opportunities for its virology assets, including lonafarnib-based regimens for hepatitis delta virus (HDV) and peginterferon lambda. Despite recent challenges, such as the discontinuation of the Phase 3 LIMT-2 study of peginterferon lambda due to safety concerns, Eiger remains committed to its primary goals.
Financially, Eiger reported total revenue of $4.6 million for Q2 2023 and $3.2 million for Q3 2023, indicating a stable financial condition supported by strategic cost reductions and workforce optimization. The company’s cash runway is extended into the fourth quarter of 2024, enhancing its capacity to pursue ongoing projects and strategic initiatives.
As of January 2024, Eiger announced a 1-for-30 reverse stock split to comply with Nasdaq's listing requirements and maintain its market position. The company is also navigating a Chapter 11 bankruptcy process to facilitate an orderly wind down of its operations and the sale of its assets, including a “stalking horse” agreement for Zokinvy.
Dr. David Apelian, with extensive experience in clinical development and regulatory affairs, leads Eiger as its CEO, guiding the company through these transformative times.
For further details and updates, visit the company’s website at www.eigerbio.com.
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced a conference call on November 3, 2022, at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The company is focused on developing innovative therapies for hepatitis delta virus (HDV) and other serious diseases, with two first-in-class therapies in Phase 3 that target viral replication. All five rare disease programs have received FDA breakthrough therapy designation.
Eiger BioPharmaceuticals, based in Palo Alto, California, announced that President and CEO David Cory will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 3:00 PM ET. Investors can participate in one-on-one meetings at the conference. A live webcast of the presentation will be available on the company's website, with a replay accessible for at least 90 days. Eiger focuses on innovative therapies for hepatitis delta virus and has several programs designated as FDA Breakthrough Therapy.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) announced it will not pursue an EUA application for peginterferon lambda to treat mild-to-moderate COVID-19, following FDA feedback. The FDA expressed concerns over the TOGETHER study's conduct, indicating that an EUA based on this data is unlikely to succeed. Instead, the FDA suggested a meeting to explore a pivotal trial for future BLA support. Eiger remains committed to peginterferon lambda's potential benefits and is assessing further development options. The company also has ongoing Phase 3 programs for other treatments, with topline data expected by year-end.
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that its President and CEO, David Cory, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 1:00 PM ET in New York City. The company focuses on innovative therapies for hepatitis delta virus (HDV) and other serious diseases, with two HDV therapies in Phase 3 trials. A live webcast of the presentation will be available on their website, along with a replay for 90 days. Eiger's HDV programs have received FDA Breakthrough Therapy designation.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced an update on its emergency use authorization (EUA) request for peginterferon lambda to treat mild-to-moderate COVID-19. Following discussions with the FDA, the agency indicated that it could not determine if criteria for the EUA submission are met. Eiger plans to provide new data from the TOGETHER study to support its application. The company remains committed to ongoing dialogue with the FDA to expedite the submission. Peginterferon lambda has shown potential efficacy in patients treated early in their infection.
Eiger BioPharmaceuticals, a biopharmaceutical company focused on therapies for hepatitis delta virus, announced its participation in three investor conferences. Key details include:
Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston, format: one-on-one meetings.
H.C. Wainwright 24th Annual Global Investment Conference scheduled for September 12 at 2:00 p.m. ET in New York, with presentations and meetings.
Baird Global Healthcare Conference on September 14 at 3:45 p.m. ET, also in New York. Live webcasts available on the company's website.
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported Q2 2022 total revenue of $4.1 million, up from $2.1 million year-over-year, driven by increased Zokinvy sales and a partnership payment. The company holds a strong cash position of $141.8 million, expected to fund operations through 2024. Major developments include ongoing FDA discussions for Peginterferon Lambda's EUA for COVID-19, the initiation of Phase 3 HDV and HI studies, and Zokinvy's EU marketing approval. However, a net loss of $21.9 million reflects ongoing investments in R&D and operational expenses.
Eiger BioPharmaceuticals, Inc. (EIGR) will host a live conference call on August 4, 2022, at 4:30 PM ET to discuss its Q2 2022 financial results and provide a business update. The call and webcast will be accessible via the company's website, with a replay available for 90 days. Eiger focuses on developing innovative therapies for hepatitis delta virus and other serious diseases, boasting a robust pipeline, including two first-in-class therapies in Phase 3 trials. All Eiger's rare disease programs have received FDA breakthrough therapy designation.
Eiger BioPharmaceuticals (EIGR) announced the European Commission's approval of Zokinvy® (lonafarnib), the first treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies, extending life by an average of 4.3 years. Approved in 30 European countries, this milestone follows U.S. approval in 2020. The treatment significantly lowers death risk by 72% in HGPS patients, who typically live until 14.5 years without intervention. Eiger aims to provide Zokinvy across Europe after successful reimbursement discussions.
Eiger BioPharmaceuticals (Nasdaq: EIGR) has appointed Lisa Kelly-Croswell to its Board of Directors. With nearly 25 years in the biopharmaceutical sector, she currently serves as Senior VP and Chief Human Resources Officer at Boston Medical Center Health System, overseeing a $5 billion organization. Her prior experience includes key HR roles at Vertex Pharmaceuticals and major companies like Cigna and Monsanto. Eiger's Chairman stated her expertise will enhance the company's strategic planning. Kelly-Croswell expressed excitement about contributing to Eiger's growth and its promising pipeline, especially in hepatitis delta virus treatments.
FAQ
What is the market cap of Eiger BioPharmaceuticals (EIGR)?
What is Eiger BioPharmaceuticals' focus?
What are Eiger's lead products?
What recent strategic changes has Eiger made?
How is Eiger financially performing?
Who is leading Eiger BioPharmaceuticals?
What is the significance of the reverse stock split?
What is avexitide used for?
What is Zokinvy® (lonafarnib)?
What is the status of Eiger's virology assets?
Where can I find more information about Eiger?
